A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors

To characterize the safety, tolerability, maximal tolerated dose (MTD), and pharmacokinetic (PK) of AM0010 after daily subcutaneous (SC) administrations in patients with advanced solid tumors as monotherapy or in combination with chemotherapy or immunotherapy.

May 13, 2016